Consumer group sues FDA over Aricept safety

September 5, 2012 by The Associated Press

(AP)—A consumer group pressing the Food and Drug Administration to remove the highest dose of an Alzheimer's disease drug from the market is suing the agency for "foot-dragging."

Public Citizen says the FDA's own reviewers found that high-dose Aricept (AR'ih-sept) doesn't work better than two low doses but has more-dangerous, potentially deadly side effects.

Public Citizen filed a petition in 2011 with the FDA. The group urged the agency to halt sales of the 23-milligram dose of Aricept and put about the high-dose risks on two low doses available under the brand and as generic pills.

The FDA has yet to act. A spokeswoman says FDA doesn't comment on litigation. Last December, the agency wrote to Public Citizen, saying it was doing a review of the case.

Explore further: Public Citizen wants withdrawal of diabetes drug

shares

Related Stories

Public Citizen wants withdrawal of diabetes drug

April 19, 2012

(AP) -- A consumer advocacy group is calling on government regulators to withdraw a diabetes drug from Novo Nordisk, saying the injectable medication raises the risk of thyroid cancer, pancreatitis and kidney failure.

Advocacy group seeks ban on pelvic surgical mesh

August 25, 2011

(AP) -- A consumer advocacy group is calling on government regulators to ban a type of surgical mesh used to treat pelvic collapse, saying it exposes patients to serious risks.

Alzheimer's drug sharply criticized by medical experts

March 23, 2012

Watching Alzheimer's disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. But a new pill formulated by a respected pharmaceutical company and approved by the Food ...

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.